S drug memantine might perform double-duty supporting binge eaters control their compulsion.

Alzheimer’s drug might reduce addictive and impulsive behavior associated with binge eating The Alzheimer's drug memantine might perform double-duty supporting binge eaters control their compulsion. Researchers have got demonstrated that memantine, a neuroprotective drug, may decrease the impulsive and addictive behavior associated with binge eating. The Boston University School of Medicine study, which appears on the web in Neuopsychopharmacology, discovered that a particular area in the mind also, the nucleus accumbens, which is responsible for addictive behaviors, facilitates the consequences of memantine www.leukeran.net . Binge-eating disorder is definitely a prevalent illness in the us, affecting more than 10 million people. It really is characterized by periods of extreme uncontrolled consumption of meals, followed by uncomfortable emotions and fullness of self-disgust.

www.leukeran.net

Prof. Winblad has more than 700 initial publications in gerontology, geriatrics and dementia research. UBC held a meeting to discuss the Cognition Initiative, a multi-sponsor consortium to develop new measures befitting use as end points in worldwide cognition trials. This initiative brings together international experts in cognition to develop new actions to expand the number of outcomes assessed also to address the necessity for improved measurement sensitivity at slight levels of impairment. Its main focus may be the capture of the patient and caregiver perspective on relevant outcomes.. United BioSource Corporation announces during ICAD 2009 the addition of Professor Winblad to its European Scientific Advisory Panel for CNS Clinical Trials United BioSource Corporation announced this summer at ICAD 2009 that Bengt Winblad, MD, PhD has joined its European Scientific Advisory Plank for CNS Clinical Trials.